Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Klinische Wirksamkeit (39 Abbildungen)
Übersicht


Zum ersten Bild Abb. 21: Telmisartan - Enalapril Abb. 22: Telmisartan - Amlodipin Abb. 23: Telmisartan - Amlodipin Aktuelles Bild - Abb. 24: Blutdrucksenkung - Nephropathie Abb. 25: Niereninsuffizienz - Wirksamkeit Abb. 26: Telmisartan - Eigenschaften Abb. 27: Morgendliche Blutdrucksenkung Zum letzten Bild
Abbildung 24: Blutdrucksenkung - Nephropathie
The Efficacy and Safety in Patients with Renal Impairment treated with Telmisartan (ESPRIT) trial was an 8-week, open-label study of telmisartan 40–80 mg in 82 patients with hypertension (DBP 90–109 mmHg) and chronic mild/moderate (GFR 30–74 ml/min/1.73 m2) or severe renal impairment (GFR <30 ml/min/1.73 m2), or requiring maintenance haemodialysis.1 Blood pressure was significantly reduced in all groups, and there were no statistically significant between-group differences in the magnitude of the reduction. Drug-related adverse events were uncommon, and were typical class effects of ARBs. There were few notable changes in laboratory parameters following telmisartan treatment. 1. Sharma AM, et al. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol 2005; 63: 250–257.
 
Blutdrucksenkung - Nephropathie
Vorheriges Bild Nächstes Bild   


Abbildung 24: Blutdrucksenkung - Nephropathie
The Efficacy and Safety in Patients with Renal Impairment treated with Telmisartan (ESPRIT) trial was an 8-week, open-label study of telmisartan 40–80 mg in 82 patients with hypertension (DBP 90–109 mmHg) and chronic mild/moderate (GFR 30–74 ml/min/1.73 m2) or severe renal impairment (GFR <30 ml/min/1.73 m2), or requiring maintenance haemodialysis.1 Blood pressure was significantly reduced in all groups, and there were no statistically significant between-group differences in the magnitude of the reduction. Drug-related adverse events were uncommon, and were typical class effects of ARBs. There were few notable changes in laboratory parameters following telmisartan treatment. 1. Sharma AM, et al. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol 2005; 63: 250–257.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung